Mindset Pharma Selects Treatment-Resistant Depression and End-of-Life Cancer Anxiety as Indications for MSP-1014, Its New Psilocybin-Inspired Clinical Candidate

0

TORONTO, Sep 09, 2021 (GLOBE NEWSWIRE) – Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic drugs to treat neurological and psychiatric disorders with unmet medical needs, today announced that it has selected treatment-resistant depression ( “DRT”) and end-of-life anxiety as initial target indications for its leading clinical candidate, MSP-1014. MSP-1014 is a new patent pending drug candidate that, based on preclinical data, shows the potential to be a safer second generation psilocybin-like therapy with reduced potential for side effects.

“Psilocybin has shown encouraging efficacy in the treatment of DRT and end-of-life cancer anxiety in a number of clinical studies and we believe our new drug candidate, MSP-1014, represents a further development. safe and more scalable compared to its predecessor psilocybin, ”said James Lanthier, CEO of Mindset. “TRD represents a large and untreated population with ⅓ of people suffering from major depressive disorders resistant to currently available treatments.1, while End of Life Angst is a major cause of depression and anxiety with limited treatment options. We see an opportunity to close a significant treatment gap with our next generation drug and plan to advance MSP-1014, along with other candidates in our library of patent-pending compounds, through the regulatory process as quickly. as possible. “

“In a direct comparison with psilocybin, MSP-1014 demonstrated a superior response to head contractions and minimal change in core body temperature, suggesting that our compound potentially produces a greater hallucinogenic response with a profile of improved security, ”said Joseph Araujo, Chief Scientific Officer of Mindset. “In addition, MSP-1014 builds on Mindset’s proprietary psilocybin synthesis process, enabling increased manufacturing efficiency and positioning us well to advance our new drug candidate to clinical trials. “

To watch a video of Mindset CEO discussing the announcement in more detail, please visit: https://youtu.be/O1NZe05u34Y.

1Jaffe, DH, Rive, B. & Denee, TR The humanistic and economic burden of treatment-resistant depression in Europe: a cross-sectional study. BMC Psychiatry 19, 247 (2019).

For more information please contact:

Investor contact:
Allison Soss / Tim Regan
KCSA strategic communication
E-mail: [email protected]
Telephone: 212-896-1267 / 347-487-6788

Company details :
James Lanthier, CEO
E-mail: [email protected]

Jason Atkinson, Vice-President, Corporate Development
E-mail: [email protected]
Telephone: 416-479-4094

About Mindset Pharma Inc.
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic drugs to treat unmet neurological and psychiatric conditions. Mindset was created to develop next-generation pharmaceutical actives that take advantage of the revolutionary therapeutic potential of psychedelic drugs. Mindset is developing several new families of new generation psychedelic compounds, as well as an innovative process for chemically synthesizing psilocybin as well as its own proprietary compounds.

For more information on Mindset, please visit our website at www.mindsetpharma.com.

Forward-looking information

This press release contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often characterized by words such as “plan”, “expect”, “plan”, “intend”, “believe”, “anticipate”, “estimate”, “power”, “Will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to various risks and uncertainties and other factors that could cause actual events or results to differ. substantially from those forecast in the forecasts. information search. Additional information regarding the risks and uncertainties associated with the Company’s activities is contained in the “Risk Factors” section of the Company’s annual information form for the fiscal year ended June 30, 2020 dated March 5, 2021. Forward-looking information included in this news release is made as of the date of this press release and the Company does not undertake to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, unless applicable law required.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS COMMUNICATION.


Source link

Share.

Leave A Reply